A Phase II Study of the Bruton's Tyrosine Kinase Inhibitor, Zanubrutinib, in Combination With Lenalidomide Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Latest Information Update: 14 Mar 2022
At a glance
- Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Lenalidomide (Primary) ; Prednisolone (Primary) ; Rituximab (Primary) ; Vincristine (Primary) ; Zanubrutinib (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms ZR2-CHOP
Most Recent Events
- 09 Mar 2022 Status changed from not yet recruiting to recruiting.
- 25 Jan 2022 New trial record